Corporate ProfilescPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery — with the goal of transforming infused therapies, advancing patient care and reducing healthcare costs.
Stock Quote SCPH (Common Stock) $13.96 - 0.22 (1.55%)
ExchangeNASDAQ
Volume30,229
Today's Open$14.29
Previous Close$14.18
Data as of 12/14/17 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: SCPH.O.  Currently trading at $13.96 with a 52 week high of $18.17 and a 52 week low of $13.02.
Current News

Dec 12, 2017

scPharmaceuticals Inc. to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

BURLINGTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that Troy A. Ignelzi, chief financial officer of scPharmaceuticals, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference at 4:30 PM ET on Thursday, December 14, 2017, at the

Read More >

Nov 29, 2017

scPharmaceuticals Inc. Announces Closing of Over-Allotment Option in its Initial Public Offering

BURLINGTON, Mass., Nov. 29, 2017 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (the “Company” or “scPharmaceuticals”) (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced it has issued an additional 894,968 shares of common stock at the initial public offering price of $14.00, resulting in additional gross proceeds of approximat

Read More >

Nov 29, 2017

scPharmaceuticals Inc. Announces Closing of Initial Public Offering

BURLINGTON, Mass., Nov. 29, 2017 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (the “Company”) a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced the closing of its initial public offering of 6,400,000 shares of common stock at a public offering price of $14.00 per share.  All of the shares sold in the offering were offered by scPharmaceutic

Read More >

Upcoming Events
There are currently no events scheduled.